08:15 AM EDT, 06/23/2025 (MT Newswires) -- ArriVent BioPharma ( AVBP ) said Monday that interim results from a global phase 1b study of firmonertinib monotherapy showed 16 months median progression-free survival for patients treated with firmonertinib 240 mg in non-small cell lung cancer with epidermal growth factor receptor PACC mutations.

A majority of patients treated at 240 mg dose remain on trial following a year, with 14.6 months median duration of response, the company said, adding that the potential treatment showed a 68.2% confirmed overall response rate at the dose level.

The trial data demonstrated strong central nervous system activity, with 41% confirmed complete response and 53% confirmed overall response in CNS evaluable disease patients, ArriVent BioPharma ( AVBP ) said.

The company also said enrollment in a global phase 3 trial will likely begin in H2.

ArriVent BioPharma's ( AVBP ) shares were up 5.1% in recent Monday premarket activity.